Medpace Holdings, Inc. $MEDP is Wasatch Advisors LP's 5th Largest Position

Wasatch Advisors LP lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 17.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 636,595 shares of the company's stock after selling 137,336 shares during the quarter. Medpace accounts for approximately 2.2% of Wasatch Advisors LP's investment portfolio, making the stock its 5th biggest holding. Wasatch Advisors LP owned 2.23% of Medpace worth $337,134,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Geneos Wealth Management Inc. increased its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new position in Medpace in the 4th quarter valued at $30,000. Allied Private Wealth LLC bought a new position in Medpace in the 2nd quarter valued at $31,000. Basecamp Wealth Advisors LLC increased its position in shares of Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company's stock valued at $33,000 after purchasing an additional 45 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $605.50 on Wednesday. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The business's fifty day moving average price is $528.36 and its 200-day moving average price is $491.85. The stock has a market capitalization of $16.90 billion, a PE ratio of 35.49, a P/E/G ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the firm posted $3.10 EPS. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the transaction, the vice president owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the business's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 31,087 shares of company stock worth $16,203,054 over the last quarter. 20.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MEDP. BMO Capital Markets lifted their target price on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research note on Friday, July 24th. Jefferies Financial Group downgraded shares of Medpace from a "buy" rating to a "hold" rating and raised their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Medpace in a research report on Thursday, July 2nd. Mizuho boosted their target price on shares of Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada boosted their target price on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $584.18.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source